Citation Impact
Citing Papers
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
2006
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Ten things you should know about protein kinases: IUPHAR R eview 14
2015
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
2004
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
2012
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Antitumor activity of HER-2 inhibitors
2004
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
2005
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity
2005
Cell mechanics and the cytoskeleton
2010 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
The evolving role of natural products in drug discovery
2005 Standout
Bioactive Natural Products from Papua New Guinea Marine Sponges
2012
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Marine natural products
1990 Standout
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Drug development from marine natural products
2008 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Marine pharmacology in 2003–2004: Anti-tumour and cytotoxic compounds
2006
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Induction of Cytoprotective Pathways Is Central to the Extension of Lifespan Conferred by Multiple Longevity Pathways
2012 StandoutNobel
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
ErbBs in lung cancer
2008
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
A cytoprotective perspective on longevity regulation
2013 StandoutNobel
Microtubules as a target for anticancer drugs
2004 Standout
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Emerging drugs for non-small-cell lung cancer
2007
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
2007
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin
2004
ROS-based lethality of Caenorhabditis elegans mitochondrial electron transport mutants grown on Escherichia coli siderophore iron release mutants
2019 StandoutNobel
Breast Cancer Treatment
2019 Standout
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
2006
The ER–Golgi intermediate compartment is a key membrane source for the LC3 lipidation step of autophagosome biogenesis
2013 StandoutNobel
Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
2010
Mitochondrial Dysfunction Confers Resistance to Multiple Drugs inCaenorhabditis elegans
2010
The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
2008
Cancer Genome Landscapes
2013 StandoutScience
Metagenomic approaches to exploit the biotechnological potential of the microbial consortia of marine sponges
2007
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
2003
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
2007
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
2010
Works of Michelle Baxter being referenced
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
2004
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
2003